NRC FORM,313

U.S. NUCLEAR REGULATORY COMMISSION

APPROVED BY OMB: NO. 3150-0120

EXPIRES: 05/31/2015

1.

(03-2014) 10 CFR 30, 32, 33, 34 35, 36, 37, 39, and 40

APPLICATION FOR MATERIALS LICENSE

Estimated burden per response to comply with this mandatory collection request: 4.3 hours. Submittal of the application is necessary to determine that the applicant is qualified and that adequate procedures exist to protect the public health and safety. Send comments regarding burden estimate to the FOIA, Privacy, and Information Collections Branch (T-5 F53), U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, or by internet e-mail to Infocollects.Resource@nrc.gov, and to the Desk Officer, Office of Information and Regulatory Affairs, NEOB-10202, (3150-0120), Office of Management and Budget, Washington, DC 20503. If a means used to impose an information collection does not display a currently valid OMB control-number, the NRC may not conduct or sponsor, and a person is not required to respond to, the information collection.

INSTRUCTIONS: SEE THE APPROPRIATE LICENSE APPLICATION GUIDE FOR DETAILED INSTRUCTIONS FOR COMPLETING APPLICATION SEND TWO COPIES OF THE ENTIRE COMPLETED APPLICATION TO THE NRC OFFICE SPECIFIED BELOW. *AMENDMENTS/RENEWALS THAT INCREASE THE SCOPE OF THE EXISTING LICENSE TO A NEW OR HIGHER FEE CATEGORY WILL REQUIRE A FEE.

APPLICATION FOR DISTRIBUTION OF EXEMPT PRODUCTS FILE APPLICATIONS WITH:

OFFICE OF FEDERAL & STATE MATERIALS AND ENVIRONMENTAL MANAGEMENT PROGRAMS DIVISION OF MATERIALS SAFETY AND STATE AGREEMENTS U.S. NUCLEAR REGULATORY COMMISSION WASHINGTON, DC 20555-000

ALL OTHER PERSONS FILE APPLICATIONS AS FOLLOWS:

IF YOU ARE LOCATED IN:

LABAMA, CONNECTICUT, DELAWARE, DISTRICT OF COLUMBIA, FLORIDA, GEORGIA, KENTUCKY, MAINE, MARYLAND, MASSACHUSETTS, NEW HAMPSHIRE, NEW JERSEY, NEW YORK, NORTH CAROLINA, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, VERMONT, VIRGINIA, VIRGIN ISLANDS, OR WEST VIRGINIA,

SEND APPLICATIONS TO:

LICENSING ASSISTANCE TEAM DIVISION OF NUCLEAR MATERIALS SAFETY
U.S. NUCLEAR REGULATORY COMMISSION, REGION I 2100 RENAISSANCE BOULEVARD, SUITE 100 KING OF PRUSSIA, PA 19406-2713

IF YOU ARE LOCATED IN:

ILLINOIS, INDIANA, IOWA, MICHIGAN, MINNESOTA, MISSOURI, OHIO, OR WISCONSIN, SEND APPLICATIONS TO:

MATERIALS LICENSING BRANCH MATERIALS LICENSING BRANCH
U.S. NUCLEAR REGULATORY COMMISSION, REGION III 2443 WARRENVILLE ROAD, SUITE 210 LISLE, IL 60532-4352

ASKA, ARIZONA, ARKANSAS, CALIFORNIA, COLORADO, HAWAII, IDAHO, KANSAS, LOUISIANA, MISSISSIPPI, MONTANA, NEBRASKA, NEVADA, NEW MEXICO, NORTH DAKOTA, OKLAHOMA, OREGON, PACIFIC TRUST TERRITORIES, SOUTH DAKOTA, TEXAS, UTAH, WASHINGTON, OR WYOMING,

SEND APPLICATIONS TO:

NUCLEAR MATERIALS LICENSING BRANCH U.S. NUCLEAR REGULATORY COMMISSION, REGION IV 1600 F. LAMAR BOULEVARD ARLINGTON, TX 76011-4511

PERSONS LOCATED IN AGREEMENT STATES SEND APPLICATIONS TO THE U.S. NUCLEAR REGULATORY COMMISSION ONLY IF THEY

WISH TO POSSESS AND USE LICENSED MATERIAL IN STATES SUB.	JECT TO U.S.NUCLEAR REGULATOR	RY COMMISSION	JURISDICTIONS.	
THIS IS AN APPLICATION FOR (Check appropriate item)	NAME AND MAILING ADDRESS OF APPLICANT (Include ZIP code)			
A. NEW LICENSE	Nordion (Canad) Inc.			
B. AMENDMENT TO LICENSE NUMBER 54-28275-02MD	447 March Road			
C. RENEWAL OF LICENSE NUMBER	Ottawa, Ontario, Canada K2K 1X8			
3. ADDRESS WHERE LICENSED MATERIAL WILL BE USED OR POSSESSED	4. NAME OF PERSON TO BE CONTACTED ABOUT THIS APPLICATION			
	Luc Desgagne			
Anywhere in the United States where the NRC has jurisdiction.	BUSINESS TELEPHONE NUMBER	BUSINESS CELLULAR TELEPHONE NUMBER		
	(613) 592-3400			
	BUSINESS EMAIL ADDRESS			
	luc.desgagne@nordion.com			
SUBMIT ITEMS 5 THROUGH 11 ON 8-1/2 X 11" PAPER. THE TYPE AND SCOPE OF INFORMATION TO BE PROVIDED IS DESCRIBED IN THE LICENSE APPLICATION GUIDE.				
5. RADIOACTIVE MATERIAL	6. PURPOSE(S) FOR WHICH LICENSED MATERIAL WILL BE USED.			
 Element and mass number; b. chemical and/or physical form; and c. maiximum amount which will be possessed at any one time. 	INDIVIDUAL(S) RESPONSIBLE FOR RADIATION SAFETY PROGRAM AND THEIR TRAINING EXPERIENCE.			
8. TRAINING FOR INDIVIDUALS WORKING IN OR FREQUENTING RESTRICTED AREAS.	9. FACILITIES AND EQUIPMENT.			
10. RADIATION SAFETY PROGRAM.	11. WASTE MANAGEMENT.			
 LICENSE FEES (Fees required only for new applications, with few exceptions*) (See 10 CFR 170 and Section 170.31) 	FEE CATEGORY	AMOUNT ENCLOSED \$		
13. CERTIFICATION. (Must be completed by applicant) THE APPLICANT UNDERSTANDS THAT ALL STATEMENTS AND REPRESENTATIONS MADE IN THIS APPLICATION ARE BINDING UPON THE APPLICANT.				
THE APPLICANT AND ANY OFFICIAL EXECUTING THIS CERTIFICATION ON BEHALF OF THE APPLICANT, NAMED IN ITEM 2, CERTIFY THAT THIS APPLICATION IS PREPARED IN CONFORMITY WITH TITLE 10, CODE OF FEDERAL REGULATIONS, PARTS 30, 32, 33, 34, 35, 36, 37, 39, AND 40, AND THAT ALL INFORMATION CONTANED HEREIN IS TRUE AND CORRECT TO THE BEST OF THEIR KNOWLEDGE AND BELIEF. WARNING: 18 U.S.C. SECTION 1001 ACT OF JUNE 25, 1948 62 STAT. 749 MAKES IT A C RIMINAL OFFENSE TO MAKE A WILLFULLY FALSE STATEMENT OR REPRESENTATION TO ANY DEPARTMENT OR AGENCY OF THE UNITED STATES AS TO ANY MATTER WITHIN ITS JURISDICTION.				
CERTIFYING OFFICER TYPED/PRINTED NAME AND TITLE	SIGNATURE		DATE	
Jackie Kavanagh Senior Manager, EHS Compliance Facility and Transport Licensing	J. Kavarag		15/06/01	
TYPE OF FEE FEE LOQ FEE CATEGORY ANOLDET RECEIVED CHRON APPROVED BY CONTRACTOR OF THE CATEGORY AND LITTLE RECEIVED CHRON CONTRACTOR OF TH	COMMENTS COMMENTS			



June 1, 2015

Licensing Assistance Team
Division of Nuclear Materials Safety Branch
U.S. Nuclear Regulatory Commission, Region 1
2100 renaissance Boulevard, Suite 100
King of Prussia, PA 19406-2713

SUBJECT: REQUEST TO AMEND MATERIALS LICENSE NO. 54-28275-02MD

To Whom This May Concern,

Please find enclosed a request to amend our NRC License 54-28275-02MD.

This amendment request is in regards to this one item only:

1- Please remove Condition 12 listed on license 54-28275-02MD.

To this effect and as per NRC's Ms. Robin Elliott's instructions attached (email dated June 1, 2015), please find the email correspondence (and its FDA attachment) between FDA and NRC regarding the FDA confirmation that Nordion (Canada) Inc. is registered with the FDA under 21 CFR 207.20(a).

Should you have additional questions, please do not hesitate to contact me by telephone (613) 592-3400 ext. 2108 or by fax (613) 592-2006 or by email: Luc.Desgagne@nordion.com.

Sincerely,

Luc Desgagné

Senior Licensing Coordinator

Licensing & Compliance

Nordion (Canada) Inc.

CC Jackie Kavanagh, Greg Fulford, Nordion

Desgagne, Luc

From: Sent:

Elliott, Robin [Robin.Elliott@nrc.gov] Monday, June 01, 2015 7:59 AM

To:

Fulford, Greg

Cc:

Desgagne, Luc; Lanzisera, Penny

Subject:

FW: Nordion Canada, Inc.

Attachments:

Nordion Canada May 22 2015.xls

Good Morning Greg,

Thanks for following up on the license condition regarding your registration with the FDA. Unfortunately, just sending the web link is not adequate.

Please print off the email and attachment below which contains verification from FDA of your registration, and send it in with a cover letter signed by a management representative requesting License Condition 12 be removed. If you have any questions, feel free to direct them to me.

Regards, Robin

From: CDER Electronic Drug Registration and Listing [mailto:EDRLS@fda.hhs.gov]

Sent: Friday, May 22, 2015 12:31 AM

To: Elliott, Robin

Subject: RE: Nordion Canada, Inc.

Robin Elliott:

This is verification of the status for Nordion (Canada) Inc. that is registered with FDA, in the eDRLs database, provided in the attachment above.

Please contact us, if we can be of further assistance eDRLs team LK

CDER Direct is the user-friendly alternative to x-form/Pragamatic for electronic portal for Structured Product Labeling (SPL) submissions to the U.S Food and Drug Administration (FDA). The portal supports the goal of the Center for Drug Evaluation and Research (CDER) to provide a user friendly, web-based system for creating, reviewing, editing and SPL submissions.

You can create an account here - https://direct.fda.gov

If you have questions concerning Drug Registration and Listing please send an email to edrls@fda.hhs.gov.

For questions relating to SPL errors please send an email to SPL@fda.hhs.gov.

For Electronic Submission Gateway questions or issues please send an email to esghelpdesk@fda.hhs.gov.

From: Elliott, Robin [mailto:Robin.Elliott@nrc.gov]

Sent: Thursday, May 21, 2015 7:13 AM

To: CDER Electronic Drug Registration and Listing

Cc: Lanzisera, Penny

Subject: RE: Nordion Canada, Inc.

Can you please tell me if you provide anything in writing to registrants as evidence of their registration?

Or is listing on your site the only evidence of their registration.

Thank you, Robin

From: CDER Electronic Drug Registration and Listing [mailto:EDRLS@fda.hhs.gov]

Sent: Tuesday, May 19, 2015 11:05 AM

To: Elliott, Robin

Subject: RE: Nordion Canada, Inc.

Robin L. Elliott:

This is a verification for the status of Nordion (Canada) Inc. is registered with the FDA in the eDRLs database and does meet the requirement for registration for the following statement below:

"Registered with the U.S. Food and Drug Administration (FDA) as the owner or operator of a drug establishment that engages in the manufacturer, preparation, propagation, compounding, or processing of a drug under 21 CFR 207.20(a)."

Please contact us, if we can be of further assistance eDRLs team LK

CDER Direct is the user-friendly alternative to x-form/Pragamatic for electronic portal for Structured Product Labeling (SPL) submissions to the U.S Food and Drug Administration (FDA). The portal supports the goal of the Center for Drug Evaluation and Research (CDER) to provide a user friendly, web-based system for creating, reviewing, editing and SPL submissions.

You can create an account here - https://direct.fda.gov

If you have questions concerning Drug Registration and Listing please send an email to edrls@fda.hhs.gov.

For questions relating to SPL errors please send an email to <u>SPL@fda.hhs.gov</u>. For Electronic Submission Gateway questions or issues please send an email to <u>esghelpdesk@fda.hhs.gov</u>.

From: Elliott, Robin [mailto:Robin.Elliott@nrc.gov]

Sent: Tuesday, May 19, 2015 8:43 AM

To: CDER Electronic Drug Registration and Listing

Cc: Lanzisera, Penny; Howe, Donna-Beth

Subject: Nordion Canada, Inc.

Hello,

I am trying to verify the status of Nordion Canada, Inc.

with respect to their registration with the FDA.

We have asked them to verify that they have met the following requirement: "Registered with the U.S. Food and Drug Administration (FDA) as the owner or operator of a drug establishment that engages in the manufacturer, preparation, propagation, compounding, or processing of a drug under 21 CFR 207.20(a)."

They sent a screen shot of your site showing them as registered here. Does this registration meet the above stated requirement?

Thank you,

Robin L. Elliott

Health Physicist
U. S. Nuclear Regulatory Commission
Region I, Division of Nuclear Materials Safety
2100 Renaissance Blvd
King of Prussia, PA 19406-2713
(610) 337-5076 voice
(610) 337-5269 fax
Robin.Elliott@nrc.gov

includes an administrative review 74-28-7 There were no administrative technical reviewer. Please no omissions or require additional	and to inform you that the initial processing which whas been performed. S-02-MD amendment of the initial processing which was been performed. S-02-MD amendment of the initial processing which was assigned to a content of the initial processing which was a content of the initial processing which w	7
Branch, who will contact you sep Your action has been assigned M	s action, please refer to this control number.	